SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Govt caps prices of more 36 drugs, vaccines

22 Sep 2014 Evaluate

In yet another negative development for pharma companies, the government has capped the prices of 36 drugs, including major anti-infectives, gastro drugs and vaccines. These medicines add to the list of ‘348’ drugs that are deemed as ‘essential’ and therefore subject to price caps and cover up-to 30% of the total drugs sold in the country. Both, global and Indian pharmaceutical industries have been hit by the wide-ranging government-imposed price-reduction over the past year.

Pharma companies selling in India have been the worst hit as the prices in the country are already lowest in the world. Indian drugmakers, including Cipla, Ranbaxy Laboratories and Cadila Healthcare are among the companies that will be affected by the latest move. Further, the National Pharmaceutical Pricing Authority (NPPA), reportedly also is contemplating upon the idea of drawing up a list of mass consumption, essential life-saving drugs which could be included in the essential medicines list. These recommendations are expected to make way to the health ministry by mid-October.

Just few days back, National Pharmaceutical Pricing Authority (NPPA) brought prices of another 43 essential medicines to treat diseases like tuberculosis or heart ailments under a control regime, even though the Delhi High Court asked the Centre and the pharmaceutical companies to resolve the drug pricing issue. Thus, bringing incremental number of medicines under the price control regime has resulted into growing friction between the Government and the pharmaceutical industry, resulting in litigation.

Back in July NPPA had brought prices of over 100 non-scheduled drugs under price control as per paragraph 19 of Drug Prices Control Order (DPCO). Organization of Pharmaceutical Producers of India’s (OPPI) had opposed the move to fix caps on the prices of over 100 drugs which were non-scheduled formulations and lie outside the scope of National List of Essential Medicines (NLEM).

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×